Key facts
- Embed BioTech’s last known valuation is $6.8M (Aug 2025).
- It has raised $2.0M; the latest was Early Stage VC ($2.0M) in Aug 2025.
- Notable investors include Imperial College London, Kayan Ventures.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Embed BioTech
- ·The full record, as it builds
Funding rounds
No funding rounds for Embed BioTech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Embed BioTech
Developer of orthopedic implant technology designed to support bone healing. The company develops implant systems that integrate electrical stimulation and mechanical stimulation at the implant interface, incorporate implantable electronic components, support interaction with biological processes at the implant surface, enabling surgeons and healthcare providers to address bone repair and integration processes in patients requiring orthopedic implantation.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2024
- Employees
- 6
- Website
- embed.bio/
- Ownership
- Privately Held (backing)
Embed BioTech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Embed BioTech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Embed BioTech in its N-PORT filings yet. We sweep new filings monthly.